Zanubrutinib is used to treat certain types of blood cancers, particularly chronic lymphocytic leukemia and lymphomas. It works by blocking a protein that helps cancer cells grow and survive.[2] Brukinsa is currently approved and in use across 39 indications[4].[1]
Brukinsa is one of 546 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
1931 competitors in COVID-19
Brukinsa
Spikevax
Aldactone
Calciferol
Nitrostat
Aquasol E
Tricor
Glucocorticoid
Achromycin V
Statin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Nov 14, 2019
BRUKINSA
NDA NDA213217
Jun 10, 2025
BRUKINSA
NDA NDA218785
Sources
Details